abrdn plc Buys 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

abrdn plc increased its stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 124.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 528,472 shares of the company’s stock after buying an additional 293,461 shares during the period. abrdn plc owned 1.29% of Vigil Neuroscience worth $898,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Verition Fund Management LLC purchased a new stake in Vigil Neuroscience in the third quarter worth about $442,000. Point72 Asset Management L.P. lifted its position in shares of Vigil Neuroscience by 7.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after purchasing an additional 115,000 shares during the period. Walleye Capital LLC lifted its position in shares of Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after purchasing an additional 92,217 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Vigil Neuroscience by 41.9% during the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after purchasing an additional 66,712 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on VIGL shares. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research note on Thursday, January 23rd. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. William Blair began coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating for the company. Finally, Wedbush lifted their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Vigil Neuroscience presently has an average rating of “Buy” and an average target price of $19.75.

Vigil Neuroscience Stock Up 0.4 %

Shares of VIGL opened at $2.65 on Tuesday. The stock has a fifty day simple moving average of $2.02 and a two-hundred day simple moving average of $2.98. The company has a market capitalization of $108.33 million, a PE ratio of -1.29 and a beta of 1.84. Vigil Neuroscience, Inc. has a 52-week low of $1.49 and a 52-week high of $6.06.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.